Optimizing CAR-T therapy delivery in the Italian healthcare system: economic and organizational insights in follicular lymphoma
Global and Regional Health Technology Assessment · 09.06.2026 · 13 (1) · 133-145
DOI: 10.33393/grhta.2026.3722 ↗Kurz gefasst
Fachartikel in der Zeitschrift Global and Regional Health Technology Assessment, online erschienen am 09.06.2026. Verfasst von Andrea Vitagliano und 8 weiteren Autor:innen. Beteiligte Einrichtung: Pharmalex Italy S.p.A., Milan - Italy. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Follicular Lymphoma (FL) is the second most common lymphoid malignancy, with 20% of patientsprogressing within 24 months of first-line therapy. Chimeric antigen receptor T-cell (CAR-T) therapies have improved outcomes in relapsed or refractory FL, yet their use requires significant resources and complex care pathways. Although outpatient CAR-T programs have shown promising safety and feasibility, limited evidence exists on their organizational, economic, and ethical implications in the Italian healthcare setting. This study compares the current CAR-T pathway for FL patients with a virtual optimized scenario incorporating outpatient management in selected phases.
Methods
A multidimensional framework was applied to assess differences between standard in-hospital care(Standard Pathway) across three Italian public hospitals (Genoa, Rome, Perugia) and a partially outpatient model(Efficient Pathway). Literature review and expert consultations validated existing practices and informed optimization criteria. Structured surveys provided quantitative and qualitative inputs. Economic modelling estimated three-year full costs using patient-level data, while organizational and ethical aspects were evaluated through Likert scales.
Results
Efficient Pathway shifted bridging therapy, post-infusion monitoring, and follow-up to outpatient settings,reducing total costs from € 611,070 (As-Is) to € 497,421 (To-Be). Organizational benefits included increasedbed capacity (average score: 4.9/6) and consumable utilization (average score: 4.3/6), while ethical gains wereobserved in treatment accessibility (average score: 4.3/6).
Conclusions
Introducing outpatient management into CAR-T phases may provide economic, organizational, andethical advantages when supported by clear eligibility criteria and structured monitoring. As CAR-T indicationsexpand, pathway redesign will be essential to ensure equitable access and sustain healthcare system resources.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Pharmalex Italy S.p.A., Milan - Italy.
- IRCCS Ospedale Policlinico San Martino, Genova - Italy.
- Azienda Ospedaliero Universitaria Policlinico Umberto I, Rome - Italy.
- Dipartimento di Medicina Traslazionale e di Precisione Sapienza, Università di Roma, Rome - Italy.
- Azienda Ospedaliera di Perugia, Perugia - Italy.
- Centro Ricerche Emato-Oncologiche, Università di Perugia, Perugia - Italy.
ORCID-Profile: Emanuele Angelucci, Maria Paola Martelli, Marianna Morani
Zitieren
APA
Vitagliano, A., Bonfanti, M., Angelucci, E., Di Rocco, A., Martelli, M. P., Sarto, E. D., Morani, M., Lucchetti, C., & Palladino, S. (2026). Optimizing CAR-T therapy delivery in the Italian healthcare system: economic and organizational insights in follicular lymphoma. Global and Regional Health Technology Assessment, 13(1), 133-145. https://doi.org/10.33393/grhta.2026.3722
Vancouver
Vitagliano A, Bonfanti M, Angelucci E, Di Rocco A, Martelli MP, Sarto ED, et al. Optimizing CAR-T therapy delivery in the Italian healthcare system: economic and organizational insights in follicular lymphoma. Global and Regional Health Technology Assessment. 2026;13(1):133-145. doi:10.33393/grhta.2026.3722
BibTeX
@article{Vitagliano2026,
author = {Vitagliano, Andrea and Bonfanti, Marzia and Angelucci, Emanuele and Di Rocco, Alice and Martelli, Maria Paola and Sarto, Elena Del and Morani, Marianna and Lucchetti, Chiara and Palladino, Simona},
title = {Optimizing CAR-T therapy delivery in the Italian healthcare system: economic and organizational insights in follicular lymphoma},
journal = {Global and Regional Health Technology Assessment},
year = {2026},
volume = {13},
number = {1},
pages = {133--145},
doi = {10.33393/grhta.2026.3722}
}
EUVIMED